Jun 19, 2020
Full results from EMPERIAL exercise ability trials presented
Jun 16, 2020
International Study of More Than 8,000 People Showed Ertugliflozin Does Not Increase Risk of Cardiac Events
Jun 15, 2020
Dapagliflozin May Help Reduce Onset of Type 2 Diabetes
Mar 20, 2020
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
Dec 13, 2019
Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure
Nov 17, 2019
Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Nov 13, 2019
Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
Nov 12, 2019
Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized
Nov 09, 2019
New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney Function
Nov 04, 2019
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®
Jun 27, 2019
National Kidney Foundation Sponsors Workshop to Examine New Therapy for Diabetic Kidney Disease
Jun 26, 2019
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Jun 11, 2019
INVOKANA® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis
Jun 10, 2019
New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria
Jun 09, 2019
Dapagliflozin Reduces Progression of Kidney Disease and Renal Death in People with Type 2 Diabetes
May 22, 2019
U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
Apr 14, 2019
INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study
Mar 28, 2019
Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
Mar 04, 2019
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors